Literature DB >> 18566294

Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages.

Jason L Johnson1, Graciela B Sala-Newby, Yasmin Ismail, Concepción M Aguilera, Andrew C Newby.   

Abstract

OBJECTIVE: An excess of metalloproteinases (MMPs) over tissue inhibitors of metalloproteinases (TIMPs) may favor atherosclerotic plaque rupture. We compared TIMP levels in nonfoamy and foam-cell macrophages (FCM) generated in vivo. METHODS AND
RESULTS: In vivo generated rabbit FCM exhibited 84% reduced TIMP-3 protein compared to nonfoamy macrophages, and immunocytochemistry revealed a TIMP-3 negative subset (28%). Strikingly, only TIMP-3 negative FCM invaded a synthetic basement membrane, and invasion was inhibited by exogenous TIMP-3. TIMP-3 negative FCM also had increased proliferation and apoptosis rates compared to TIMP-3 positive cells, which were retarded by exogenous TIMP-3; this also reduced gelatinolytic activity. TIMP-3 negative FCM were found at the base of advanced rabbit plaques and in the rupture-prone shoulders of human plaques. To explain the actions of low TIMP-3 we observed a 26-fold increase in MT1-MMP (MMP-14) protein in FCM. Adding an MT1-MMP neutralizing antibody reduced foam-cell invasion, apoptosis, and gelatinolytic activity. Furthermore, MT1-MMP overexpressing and TIMP-3 negative FCM were found at the same locations in atherosclerotic plaques.
CONCLUSIONS: These results demonstrate that TIMP-3 is downregulated in a distinct subpopulation of FCM which have increased MMP-14. These cells are highly invasive and have increased proliferation and apoptosis, all properties expected to destabilise atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566294      PMCID: PMC2851011          DOI: 10.1161/ATVBAHA.108.170548

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Enhanced expression of matrix metalloproteinase-3, -12, and -13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis.

Authors:  A Y Jeng; M Chou; W K Sawyer; S L Caplan; J Von Linden-Reed; M Jeune; M F Prescott
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

Review 2.  Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.

Authors:  Andrew C Newby
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

3.  Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity.

Authors:  A B Zaltsman; S J George; A C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

4.  Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo.

Authors:  Alexander J Chase; Mark Bond; Martin F Crook; Andrew C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

5.  Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism.

Authors:  Stéphanie Langlois; Geneviève Di Tomasso; Dominique Boivin; Christian Roghi; Gillian Murphy; Denis Gingras; Richard Béliveau
Journal:  Exp Cell Res       Date:  2005-07-15       Impact factor: 3.905

6.  Accelerated apoptosis in the Timp-3-deficient mammary gland.

Authors:  J E Fata; K J Leco; E B Voura; H Y Yu; P Waterhouse; G Murphy; R A Moorehead; R Khokha
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

7.  Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions.

Authors:  Joseph J Boyle; Peter L Weissberg; Martin R Bennett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

8.  Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design.

Authors:  Bart A N Verhoeven; Evelyn Velema; Arjan H Schoneveld; Jean Paul P M de Vries; Peter de Bruin; Cees A Seldenrijk; Dominique P V de Kleijn; Els Busser; Yolande van der Graaf; Frans Moll; Gerard Pasterkamp
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators.

Authors:  T B Rajavashisth; X P Xu; S Jovinge; S Meisel; X O Xu; N N Chai; M C Fishbein; S Kaul; B Cercek; B Sharifi; P K Shah
Journal:  Circulation       Date:  1999-06-22       Impact factor: 29.690

10.  Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.

Authors:  Zamaneh Kassiri; Gavin Y Oudit; Otto Sanchez; Fayez Dawood; Fazilat F Mohammed; Robert K Nuttall; Dylan R Edwards; Peter P Liu; Peter H Backx; Rama Khokha
Journal:  Circ Res       Date:  2005-07-21       Impact factor: 17.367

View more
  31 in total

Review 1.  The role of matrix metalloproteinases in atherothrombosis.

Authors:  Daniel F J Ketelhuth; Magnus Bäck
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

2.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Authors:  F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

3.  A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules.

Authors:  Cyril J Craven
Journal:  Theor Biol Med Model       Date:  2014-09-14       Impact factor: 2.432

4.  Tissue inhibitor of metalloproteinases-3 moderates the proinflammatory status of macrophages.

Authors:  Sean E Gill; Sina A Gharib; Eli M Bench; Samuel W Sussman; Roy T Wang; Cliff Rims; Timothy P Birkland; Ying Wang; Anne M Manicone; John K McGuire; William C Parks
Journal:  Am J Respir Cell Mol Biol       Date:  2013-11       Impact factor: 6.914

5.  Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke.

Authors:  Chun-Jun Li; Yu Liu; Yan Chen; Demin Yu; Kevin Jon Williams; Ming-Lin Liu
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

6.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

7.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

8.  Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes.

Authors:  Andrew C Newby; Sarah J George; Yasmin Ismail; Jason L Johnson; Graciela B Sala-Newby; Anita C Thomas
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

9.  Regulation and function of tissue inhibitor of metalloproteinase (TIMP) 1 and TIMP3 in periovulatory rat granulosa cells.

Authors:  Feixue Li; Thomas E Curry
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

10.  Selenoproteins regulate macrophage invasiveness and extracellular matrix-related gene expression.

Authors:  Bradley A Carlson; Min-Hyuk Yoo; Yasuyo Sano; Aniruddha Sengupta; Jin Young Kim; Robert Irons; Vadim N Gladyshev; Dolph L Hatfield; Jin Mo Park
Journal:  BMC Immunol       Date:  2009-10-28       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.